Eyenovia Announces Confirmatory Results from Second MicroStat Phase III Registration Study for Mydriasis Biotech Investing
Cytokinetics Announces Initiation of Phase 1 Clinical Study of AMG 594, a Cardiac Troponin Activator Biotech Investing
Ovid Therapeutics Announces Pricing of $30 Million of Securities in Concurrent Public Offerings of Common and Preferred Stock Biotech Investing
